Focusing on patients with diabetes complicated with pulmonary infection, the purpose of this study is: 1) to identify the epidemiology, etiologic spectrum and status of diagnosis and treatment; 2) to explore the lower respiratory microenvironment and host immune response and then make an application in clinic.
Investigators perform a cross-sectional multicenter study on patients with pulmonary infection. All patients receive clinical questionnaires, laboratory examinations and treatment monitoring. Routine clinical pathogen culture and mNGS are both carried out on pathogen detection. Among participants in IDSeq UltraTM group, 1:2 nested case-control study is carried out involving 77 cases from pulmonary-infected group paired with 154 control cases and peripheral blood RNA-seq is carried out between pneumonia patients with diabetes and pneumonia patients without diabetes matched for gender, age and fasting blood-glucose. The final purpose is to find out the difference in etiologic spectrum and host immune on lower respiratory infection between diabetes patients and controls. Now investigators wish to register this study to do a further research, in order to improve the diagnosis value of diabetes complicated with pulmonary infection and to reduce the mortality.
Study Type
OBSERVATIONAL
Enrollment
300
pathogen detection
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
RECRUITINGSurvival at 28 Days
28 days from date of diagnosis of pulmonary infection until the date of death from any cause
Time frame: 28 days from date of diagnosis of pulmonary infection until the date of death from any cause, whichever came first
Survival at 14 Days
14 days from date of diagnosis of pulmonary infection until the date of death from any cause
Time frame: 14 days from date of diagnosis of pulmonary infection until the date of death from any cause, whichever came first
Survival at 7 Days
7 days from date of diagnosis of pulmonary infection until the date of death from any cause
Time frame: 7 days from date of diagnosis of pulmonary infection until the date of death from any cause, whichever came first
72h Treatment Response
response after infection treating 72 hours
Time frame: disease treating 72 hours
Hospitalization Time
the time of hospital stay including ordinary sickroom and ICU of patients from different groups
Time frame: Every 6 months from date of diagnosis of pulmonary infection until the date of death from any cause, assessed up to 3 years
CURB-65 Score
Differences in confusion, urea, respiratory rate and age 65 scoring system from different groups.
Time frame: Every 6 months from date of diagnosis of pulmonary infection until the date of death from any cause, assessed up to 3 years
Inflammatory Parameters
Differences in CRP, PCT, IL-6, IL-8, TNF-α from different groups.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Day 0, day 3, day7-14 and final result from date of diagnosis of pulmonary infection until the date of death or cure from any cause, assessed up to 1 years
Cell-mediated Immunoserologic Indexs
Differences of CD3, CD4 and CD8 in different groups in order to research on cell-mediated immunity of patients with or without diabetes and pulmonary infection
Time frame: Day 0, day 3, day7-14 and final result from date of diagnosis of pulmonary infection until the date of death or cure from any cause, assessed up to 1 years
PSI Indexs
Pneumonia severity index grade, including age, comorbidities, signs, blood gases
Time frame: Day 0, day 3, day7-14 and final result from date of diagnosis of pulmonary infection until the date of death or cure from any cause, assessed up to 1 years
SOFA Indexs
Sequential Organ Failure Assessment
Time frame: Day 0, day 3, day7-14 and final result from date of diagnosis of pulmonary infection until the date of death or cure from any cause, assessed up to 1 years